DiaSorin has received from the American Food and Drug Administration the authorization for the marketing in the United States of a new immunoassay developed for the quantitative determination of vitamin D levels. DiaSorin is a company active in the market of vitamin D tests, with more than 50 % of market share globally.
"In the vitamin D market - commented Carlo Rosa, CEO of the DiaSorin Group - the strong increase in interest from the medical community has generated rapid growth in volumes forcing laboratories to provide quality results with rapid response times" .
